Scholarlink

<p>Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to estimate mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). At 12&#xa0;weeks, pemvidutide significantly reduced liver fat content (MD − 52.90, 95% CI − 71.60 to − 34.20, <i>P</i> &lt; 0.00001), CAP score (MD − 38.30, 95% CI − 70.69 to − 5.91, <i>P</i> = 0.02), body weight (MD − 3.50, 95% CI − 5.00 to − 2.00, <i>P</i> &lt; 0.00001), and blood pressure. At 24&#xa0;weeks, improvements were seen in ALT (MD − 18.09, 95% CI − 30.12 to − 6.06, <i>P</i> = 0.003), AST (MD − 13.02, 95% CI − 21.84 to − 4.20, <i>P</i> = 0.004), LFC (MD − 45.51, 95% CI − 52.70 to − 38.33, <i>P</i> &lt; 0.00001), and ELF score (MD − 0.44, 95% CI − 0.77 to − 0.11, <i>P</i> = 0.01). Safety was comparable to placebo except for higher mild-to-moderate nausea (<i>P</i> &gt; 0.05). Pemvidutide significantly improves hepatic and metabolic parameters in MASLD/MASH with acceptable tolerability. Larger, longer trials are warranted to confirm antifibrotic efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Islam Rajab,
  • Ahmed Emara,
  • Mohamed Saad Rakab,
  • Ahmed Adel Abdel Azim,
  • Heba Aboeldahab,
  • Omar F. Abbas,
  • Ryan A. Rahman,
  • Raffi Karagozian

摘要

Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to estimate mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). At 12 weeks, pemvidutide significantly reduced liver fat content (MD − 52.90, 95% CI − 71.60 to − 34.20, P < 0.00001), CAP score (MD − 38.30, 95% CI − 70.69 to − 5.91, P = 0.02), body weight (MD − 3.50, 95% CI − 5.00 to − 2.00, P < 0.00001), and blood pressure. At 24 weeks, improvements were seen in ALT (MD − 18.09, 95% CI − 30.12 to − 6.06, P = 0.003), AST (MD − 13.02, 95% CI − 21.84 to − 4.20, P = 0.004), LFC (MD − 45.51, 95% CI − 52.70 to − 38.33, P < 0.00001), and ELF score (MD − 0.44, 95% CI − 0.77 to − 0.11, P = 0.01). Safety was comparable to placebo except for higher mild-to-moderate nausea (P > 0.05). Pemvidutide significantly improves hepatic and metabolic parameters in MASLD/MASH with acceptable tolerability. Larger, longer trials are warranted to confirm antifibrotic efficacy.